Mechanisms of Therapy Resistance in Lung Cancer
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Molecular Cancer Biology".
Deadline for manuscript submissions: closed (15 March 2024) | Viewed by 983
Special Issue Editor
2. Medical Oncology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, 40138 Bologna, Italy
Interests: non-small cell lung cancer; immunotherapy; therapy resistance; special populations; thymic epithelial tumors
Special Issue Information
Dear Colleagues,
This Special Issue, titled "Mechanisms of Therapy Resistance in Lung Cancer", delves into the intricate landscape of personalized therapy for lung cancer, with a keen focus on understanding and overcoming mechanisms of resistance. Lung cancer treatment has evolved significantly, with personalized approaches emerging as a cornerstone. This Special Issue emphasizes the challenges posed by therapy resistance that hinder the effectiveness of treatments like immunotherapy and targeted therapy. Personalized therapy tailors treatment strategies to individual patients based on their tumors' genetic, molecular, and immunological characteristics. Immunotherapy has revolutionized lung cancer treatment by leveraging the immune system to combat cancer cells. However, a critical concern is the development of resistance, where tumors become less responsive to immunotherapeutic interventions. This Special Issue delves into the underlying mechanisms driving such resistance, be it through immune evasion, microenvironment alterations, or tumor cell heterogeneity. Similarly, targeted therapy, which aims to inhibit specific molecular drivers of cancer growth, is confronted by the emergence of resistance mechanisms. These may arise due to mutations, alterations in signaling pathways, or clonal evolution of tumor cells. The collection of articles in this Special Issue sheds light on the intricate molecular and cellular processes that enable tumors to evade targeted treatments, providing insights into potential strategies to overcome or prevent resistance.Finally, the subtle divergence between the oncogene and non-oncogene-addicted disease underlines the growing importance of other aspects such as clinical conditions, body composition, and comedications. This Special Issue aims to enhance our understanding of the complex mechanisms underlying therapy resistance in lung cancer by gathering research from diverse perspectives. The goal is to inform the development of innovative therapeutic approaches that can surmount these challenges and improve patient outcomes.
Dr. Andrea De Giglio
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- lung cancer
- immunotherapy
- targeted therapy
- resistance mechanisms
- oncogene-addicted
- non-oncogene addicted
